Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.55 |
| ▸ | MEN1 | O00255 | 7/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5474904 | 0.85 | KMT2A (0.66) | KMT2AMEN1POLBLMNAALDH1A1 | |
| SCHEMBL5478426 | 0.83 | KMT2A (0.57) | KMT2AMEN1POLBLMNAALDH1A1 | |
| SCHEMBL27295451 | 0.82 | DRD3 (0.57) | KMT2AMEN1POLBMAPTTP53 | |
| SCHEMBL25754768 | 0.81 | ACHE (0.51) | KMT2AMEN1POLBLMNAALDH1A1 | |
| SCHEMBL25754850 | 0.81 | MEN1 (0.55) | KMT2AMEN1ATMMAPTTP53 | |
| SCHEMBL5467487 | 0.81 | VCAM1 (0.58) | KMT2AMEN1POLBMAPTTP53 | |
| SCHEMBL4104412 | 0.79 | KMT2A (0.66) | KMT2AMEN1POLBLMNAALDH1A1 | |
| SCHEMBL5461095 | 0.78 | KMT2A (0.61) | KMT2AMEN1POLBLMNAALDH1A1 | |
| SCHEMBL6623873 | 0.77 | KMT2A (0.46) | KMT2AMEN1POLBALDH1A1MAPT | |
| SCHEMBL5467408 | 0.77 | ALDH1A1 (0.62) | KMT2AMEN1POLBLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | TRAP1, PINK1, TP53BP1 | KMT2A 4864/4885MEN1 3902/4885POLB 1494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.